27  0 (0%)		06-10 16:00
Open: 26.985 High: 27 Volume: 4,262,878		Pre. Close: 27 Low: 26.98 Market Cap: 1,438(M)

Short term
Mid term
Targets	6-month :	31.53	1-year :	36.83
Resists	First :	27	Second :	31.53
Pivot price	26.91
Supports	First :	26.8	Second :	26.68
MAs	MA(5) :	26.99	MA(20) :	26.88
	MA(100) :	20.3	MA(250) :	16.27
MACD	MACD :	0.6	Signal :	0.8
%K %D	K(14,3) :	100	D(3) :	99.6
RSI	RSI(14): 76
52-week	High :	27	Low :	9.82

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ KALV ] has closed below upper band by 24.7%. Bollinger Bands are 91.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	27.03 - 27.16	27.16 - 27.27
Low:	26.68 - 26.83	26.83 - 26.97
Close:	26.77 - 27.01	27.01 - 27.21

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Mon, 22 Jun 2026
KalVista Pharmaceuticals, Inc. SEC Filing (Jun 22, 2026) - Stock Titan

Thu, 11 Jun 2026
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals - Business Wire

Thu, 11 Jun 2026
KalVista Pharmaceuticals Sets $1,606.28 Cash Conversion for 3.25% Converts via Supplemental Indenture - TradingView

Thu, 04 Jun 2026
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Tue, 19 May 2026
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Business Wire

Wed, 13 May 2026
Chiesi (NASDAQ: KALV) offers $27.00 per share to acquire KalVista - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	53 (M)
Shares Float	38 (M)
Held by Insiders	1.7 (%)
Held by Institutions	136.8 (%)
Shares Short	6,840 (K)
Shares Short P.Month	15,160 (K)

EPS	-3.95
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.38
Profit Margin	-118.8 %
Operating Margin	-57.4 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	1.09
Sales Per Share	2.15
EBITDA (p.s.)	-2.61
Qtrly Earnings Growth	0 %
Operating Cash Flow	-89 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-6.86
PEG Ratio	0
Price to Book value	-71.06
Price to Sales	12.55
Price to Cash Flow	-16.1

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.